

THE REST OF YOUR LIFE

The Challenges of Caring for an Aging Parent

Now in his fifth year of dementia, 86-year-old Leonard Winakur doesn't know what day it is. If he's not sleeping when his son, Dr. Jerald Winakur, drops by for a visit (as Dr. Winakur does nearly every day), sometimes he'll engage his son in superficial conversation. Other times he's abrasive and says things like "You ought to come around more often" or "You're not my son."

"As my brother Michael says, he thinks it's always a good visit when he can get my father to laugh," said Dr. Winakur, who practices internal medicine and geriatrics in San Antonio. "We're able to do that on occasion."

Even though Leonard's dementia and physical health continue to worsen, Dr. Winakur and his brother do what they can to keep their father at home with his

wife, Frances. That includes sharing the \$1,500/month cost of assistance from two home health aides.

"My brother and I are my parents' only real social activity, so we feel we need to go over there frequently, not only to check on them but also to spend time with them," said Dr. Winakur. "My brother does that task on the weekends when I'm off from my doctoring life, and I try to spend time with my

wife. During the week, I'll generally go by my parents' house every day, usually after work. My wife helps me a lot. My mother's big outing every week is to go to the beauty shop, something she's done for 50 years, probably. My brother or I will take her in the morning to her appointment, and my wife will pick her up and take her out to lunch."

To complicate the caregiving situation, Frances has developed severe macular degeneration and is unable to perform some activities of daily living.

"I'm running kind of a mini two-bed nursing home in their house," said Dr. Winakur, who is on the faculty at the Center for Medical Humanities and Ethics at the University of Texas, San Antonio. "I've had many conversations with my mother about maybe moving her into an assisted-living situation where there might be a dementia unit on the same campus. But she won't consider that—at least not now. They're most comfortable in their own home. Even though I as a medical professional know there are 'other levels of care' available for them, keeping them home is what will make them most comfortable now."

The circumstances frustrate him in the sense that "you don't want to watch this [decline] happening to them, but it is happening," he said.

Though he shares caregiving duties with his brother, Dr. Winakur noted that his mother carries the bulk of the burden. She lives with Leonard's erratic behavior 24 hours a day, 7 days a week. "Every year we try to get her to go away for a week and visit relatives back east. One of us—usually my brother—will take her, and I will stay with my father. It should be more [often] than that, but she won't go. She knows my father gets agitated when she isn't there. He can't remember that she's gone away for a visit. He thinks something's wrong. It's a trying time for him. My mother knows it is, which is one of the reasons that keeps her from going," he says.

He was quick to note that it takes "great effort" to keep his parents at home. It is expensive, frustrating, and depleting, "but it can be done. We've been doing it for 4 years." Dr. Winakur knows something will disrupt the current balance of care. His father might become acutely ill or break a hip. "That will necessitate a change," he said. "What will happen then is that my father will most likely end up in some sort of long-term-care facility. And my mother will probably need ongoing help if she elects to stay at home. Then I'll have one parent in a long-term-care facility and one parent at home."

For him, the events have underscored the importance of discussing end-of-life issues with parents long before an actual crisis arises. "I read a statistic that 75% of Americans haven't had the kind of in-depth conversation with their siblings and their parents about end-of-life issues," Dr. Winakur noted. "[These discussions] need to be had. As doctors, we need to take the initiative with our elderly parents."

Dr. Robert Kane said his mother's great-
Continued on following page

ZOVIRAX® (acyclovir) Cream 5% Soothes at the Site to Heal Herpes Fast

- Targeted treatment soothes at the site¹
- Significantly shortens lesion duration vs placebo*¹
- Significantly shortens pain duration vs placebo*¹

* Shorter duration of episode: in study 1, acyclovir (n=324) 4.3 days vs vehicle (n=346) 4.8 days (P=0.010). In study 2, acyclovir (n=328) 4.6 days vs vehicle (n=343) 5.2 days (P=0.007). Shorter duration of pain: in study 1, acyclovir (n=334) 2.9 days vs vehicle (n=352) 3.2 days (P=0.024). In study 2, acyclovir (n=348) 3.1 days vs vehicle (n=351) 3.5 days (P=0.027).

Reference: 1. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T, for The Acyclovir Cream Study Group. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. *Antimicrob Agents Chemother.* 2002;46:2238-2243.

ZOVIRAX®
(acyclovir)
Cream 5%

INDICATIONS AND USAGE

ZOVIRAX Cream is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and adolescents (12 years of age and older).

CONTRAINDICATIONS

ZOVIRAX Cream is contraindicated in patients with known hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.

PRECAUTIONS

General: ZOVIRAX Cream is intended for cutaneous use only and should not be used in the eye or inside the mouth or nose. ZOVIRAX Cream should only be used on herpes labialis on the affected external aspects of the lips and face. Because no data are available, application to human mucous membranes is not recommended. ZOVIRAX Cream has a potential for irritation and contact sensitization (see ADVERSE REACTIONS). The effect of ZOVIRAX Cream has not been established in immunocompromised patients.

Drug Interactions: Clinical experience has identified no interactions resulting from topical or systemic administration of other drugs concomitantly with ZOVIRAX Cream.

Carcinogenesis, Mutagenesis, Impairment or Fertility: Systemic exposure following topical administration of acyclovir is minimal. Dermal carcinogenicity studies were not conducted. Results from the studies of carcinogenesis, mutagenesis and fertility are not included in the full prescribing information for ZOVIRAX Cream due to the minimal exposures of acyclovir that result from dermal application. Information on these studies is available in the full prescribing information for ZOVIRAX Capsules, Tablets, and Suspension and ZOVIRAX for Injection.

Pregnancy: Teratogenic Effects: Pregnancy Category B. Acyclovir was not teratogenic in the mouse, rabbit, or rat at exposures greatly in excess of human exposure. There are no adequate and well-controlled studies of systemic acyclovir in pregnant women. A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of birth defects approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects

or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses. Systemic acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: It is not known whether topically applied acyclovir is excreted in breast milk. Systemic exposure following topical administration is minimal. After oral administration of ZOVIRAX, acyclovir concentrations have been documented in breast milk in 2 women and ranged from 0.6 to 4.1 times the corresponding plasma levels. These concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0.3 mg/kg/day. Nursing mothers who have active herpetic lesions near or on the breast should avoid nursing.

Geriatric Use: Clinical studies of acyclovir cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Systemic absorption of acyclovir after topical administration is minimal (see CLINICAL PHARMACOLOGY).

Pediatric Use: Safety and effectiveness in pediatric patients less than 12 years of age have not been established.

ADVERSE REACTIONS

In 5 double-blind, placebo-controlled trials, 1,124 patients were treated with ZOVIRAX Cream and 1,161 with placebo (vehicle) cream. ZOVIRAX Cream was well tolerated; 5% of patients on ZOVIRAX Cream and 4% of patients on placebo reported local application site reactions.

The most common adverse reactions at the site of topical application were dry lips, desquamation, dryness of skin, cracked lips, burning skin, pruritus, flakiness of skin, and stinging on skin; each event occurred in less than 1% of patients receiving ZOVIRAX Cream and vehicle. Three patients on ZOVIRAX Cream and 1 patient on placebo discontinued treatment due to an adverse event.

An additional study, enrolling 22 healthy adults, was conducted to evaluate the dermal tolerance of ZOVIRAX Cream compared with vehicle using single occluded and semi-occluded patch testing methodology. Both ZOVIRAX Cream and vehicle showed a high and cumulative irritation potential. Another study, enrolling 251 healthy adults, was conducted to evaluate the contact sensitization potential of ZOVIRAX Cream using repeat insult patch testing methodology. Of 202 evaluable subjects, possible cutaneous sensitization reactions were observed in the same 4 (2%) subjects with both ZOVIRAX Cream and vehicle, and these reactions to both ZOVIRAX Cream and vehicle were confirmed in 3 subjects upon rechallenge. The sensitizing ingredient(s) has not been identified.

The safety profile in patients 12 to 17 years of age was similar to that observed in adults.

Observed During Clinical Practice: In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of acyclovir cream. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to acyclovir cream.

General: Angioedema, anaphylaxis.

Skin: Contact dermatitis, eczema, application site reactions including signs and symptoms of inflammation.

OVERDOSAGE

Overdosage by topical application of ZOVIRAX Cream is unlikely because of minimal systemic exposure (see CLINICAL PHARMACOLOGY).

DOSAGE AND ADMINISTRATION

ZOVIRAX Cream should be applied 5 times per day for 4 days. Therapy should be initiated as early as possible following onset of signs and symptoms (i.e., during the prodrome or when lesions appear). For adolescents 12 years or age and older, the dosage is the same as in adults.

HOW SUPPLIED

Each gram of ZOVIRAX Cream 5% contains 50 mg acyclovir in an aqueous cream base. ZOVIRAX Cream is supplied as follows:

2-g tubes (NDC 64455-994-42).

5-g tubes (NDC 64455-994-45).

Store at or below 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature).

Manufactured by

GlaxoSmithKline
Research Triangle Park, NC 27709
for

BIOVAIL
Pharmaceuticals, Inc.

Bridgewater, NJ 08807

©2005 GlaxoSmithKline. All rights reserved.

BR-2061

January 2005



Soothes the Outbreak



ZOVIRAX is a registered trademark of GlaxoSmithKline.
© 2005 Biovail Pharmaceuticals, Inc.

ZOV431A1105

December 2005

Continued from previous page

est fear was losing her independence. That fear was realized in 1999 when Ruth Kane suffered a stroke at the age of 84 in her Florida condominium. A stepwise decline in health led to her death in a nursing home 3 years later, despite the best efforts of Dr. Kane, an international expert in long-term care, and his sister, Joan C. West, to “get the system to perform the way it should.”

First, there was a brief hospitalization in Florida and a move to a rehabilitation hospital near Ms. West in Long Island, N.Y., where Ruth was able to regain her ability to perform most activities of daily living.

Then, Ruth was moved into an assisted living facility, where she was hospitalized several times for heart failure and her overall physical and mental health began to decline. From there, she was moved into another assisted-living facility in the area known for its special dementia care. Nine months later, she entered a nursing home, where she died after a 3-month stay.

“I had a good network of people who could find geriatricians to care for my mother in the various places she was,” said Dr. Kane, who holds the endowed chair in long-term care and aging at the University of Minnesota School of Public Health, Minneapolis. “But that didn’t make the care good. For example, the geriatrician who was caring for her did not necessarily have admitting privileges in the hospital they would take her to when she fell down in assisted living.”

Although Dr. Kane and his sister discussed having Ruth move in with one of them when she completed her rehabilitation, they determined that would not work. “The only reasonable approach would have been to set her up in an apartment and bring in 24-hour care,” Dr. Kane said. “She was so hard on people who took care of her that it would have been a con-

stant battle just keeping the roster full.”

Dr. Kane and Ms. West cowrote a book about the frustrations they experienced trying to arrange long-term care for Ruth, called “It Shouldn’t Be This Way: The Failure of Long-Term Care” (Nashville: Vanderbilt University Press, 2005). Three key lessons he learned from the ordeal were:

► **Be wary about whom you trust.** “Discharge planners are not your advocates,” he said. “Their job is to move people out of hospitals. If you’re looking for a doctor to take care of your mother, I would probably start with the American Geriatrics Society. If you’re looking for an assisted-living facility, I would try and find somebody

I trust in the area who can tell me where the good places are.”

► **Choose your battles carefully.** It’s easy to fall into an unequal negotiating position when arranging for the care of a loved one, even if you know more than the people who are delivering the care. “You can’t afford to either antagonize them or to push them to a point where they say, ‘We just can’t do the job,’” Dr. Kane said.

► **Assume a leadership role.** Dr. Kane said he draws inspiration from the Howard Beale character portrayed by Peter Finch in the 1976 film “Network,” who got people to shout, “I’m mad as hell, and I’m not going to take it anymore!” Physicians

“ought to be advocates for major reform in the way health care is delivered, to recognize that we live in a world of chronic disease and that the acute care fixation that we have in our current health care system is never going to do the job,” he said.

To help bring about such reform, Dr. Kane founded Professionals with Personal Experience in Chronic Care, a group of more than 700 physicians, nurses, and other health care workers whose main purpose is to advocate for improvements in the way long-term care is delivered. (For information, visit www.ppecc.org.) ■

By Doug Brunk, San Diego Bureau

Book Selections For Caregivers

“Caregiving at Home,” by Dr. William Leahy and the editors of Hartman Publishing (Albuquerque: Hartman Publishing, 2005).

“How to Care for Aging Parents,” by Virginia Morris (New York: Workman Publishing, 2004).

“It Shouldn’t Be This Way: The Failure of Long-Term Care,” by Dr. Robert L. Kane and Joan C. West (Nashville, Tenn.: Vanderbilt University Press, 2005).

“Meeting the Challenges of Chronic Illness,” by Dr. Robert L. Kane, Reinhard Priester, J.D., and Annette M. Totten, Ph.D. (Baltimore: The Johns Hopkins University Press, 2005).

“Our Parents, Ourselves: How American Health Care Imperils Middle Age and Beyond,” by Judith Steinberg Turiel (Berkeley: University of California Press, 2005).



Your non-prescription prescription

Cetaphil® cleansers and moisturizers are clinically proven to enhance therapeutic outcomes when used as the foundation for any skin care regimen. The restorative and protective power of Cetaphil® helps speed the healing of common skin conditions and maintain healthy skin.¹



EVERY BODY BENEFITS

www.cetaphil.com



Reference: 1. Data on file. Galderma Laboratories.

© 2006 Galderma Laboratories, L.P. Galderma and Cetaphil are registered trademarks.

Galderma Laboratories, L.P. 14501 N. Freeway, Fort Worth, TX 76177

CET-671

Printed in USA

01/06